Emeritus Research   Report issue

For profit Phase 1 Phase 2
Founded: Melbourne Australia (2020)

Organization Overview

First Clinical Trial
2020
NCT04153409
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Emeritus Research

Active Ingredients

Drugs in Phase 2 Trials (1)

lat8881 (1 trial)

Drugs in Phase 1 Trials (1)

olp-1002 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Migraine Disorders (Phase 2)

Osteoarthritis (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 2